Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure regarding its Letter of Intent (LOI) for a biopharmaceutical contract manufacturing agreement with a Europe-based pharmaceutical company, extending the contract period and disclosure postponement deadline for the counterparty’s identity from October 31, 2024, to December 31, 2024, upon the customer’s request.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: (Correction) Major Management Matters Related to Investment Decisions
- Original Filing Date: April 25, 2022
- Reason for Correction: Change in disclosure postponement date upon customer request
- Key Correction Items:
- Contract Period: (Before) 2022.04.25 – 2024.10.31 ➔ (After) 2022.04.25 – 2024.12.31
- Expected Counterparty Disclosure Date: (Before) Prior to October 31, 2024 ➔ (After) Prior to December 31, 2024
- Postponement Deadline: (Before) October 31, 2024 ➔ (After) December 31, 2024
- LOI Details (As Revised in Filing):
- Title: Signing of Letter of Intent for Biopharmaceutical Contract Manufacturing Agreement
- Counterparty: Pharmaceutical company based in Europe
- Contract Amount: KRW 154,093,728,300 (USD 124,099,000, applied exchange rate KRW 1,241.70 per USD on initial disclosure date Apr 25, 2022)
- LOI Signing Date: April 25, 2022
- Contract Period: April 25, 2022 – December 31, 2024
- Contract Amount to Revenue Ratio: 9.38% (Based on recent annual revenue of KRW 1,568,006,928,039 at initial disclosure)
- Disclosure Postponement Details:
- Postponement Item: Contract Counterparty
- Reason for Postponement: Business confidentiality
- Postponement Deadline: December 31, 2024
- Other Important Details:
- The contract amount is legally binding, and details will be disclosed upon execution of a definitive agreement.
- The counterparty is scheduled to be disclosed prior to December 31, 2024, subject to change.
- Related Disclosures:
- April 25, 2022: Major Management Matters Related to Investment Decisions
- Multiple correction filings between August 31, 2022, and August 29, 2024
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Postponement Extension and Schedule for Counterparty Disclosure
This correction disclosure provides notice that the contract period and confidentiality postponement deadline for the counterparty’s identity under the biopharmaceutical LOI with a Europe-based company have been extended to December 31, 2024, at the client’s request.
Tracking subsequent official filings regarding the execution of a definitive contract, the disclosure postponement schedule, and counterparty details is essential.
Relevant developments can be verified in subsequent official disclosures and periodic filings.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
